Amgen has delivered a powerful run in recent years, and the question now is whether the current share price lines up with the cash flows that underpin the business. With the stock trading around recent highs, investors are asking how much of Amgen's future cash generation is already reflected in today's valuation.
- Amgen has returned 133.2% over the past 5 years, which puts real pressure on the numbers to show that the cash it can generate justifies that kind of long haul performance.
- The push behind LUMAKRAS and related precision medicine efforts, including investment in companies like Arboretum LifeSciences, can shape future cash flows by influencing how quickly new treatments scale and how much capital is required to support them.
- Prefer to judge Amgen on earnings? See what Amgen's 25.7x P/E says about the price.
The issue now is whether the cash flows that Amgen can produce over time, as captured by a Discounted Cash Flow (DCF) intrinsic value estimate, are enough to support where the stock trades today.
If you are weighing Amgen's cash flow outlook against its share price and want a reference point, it can help to compare it with 29 high quality undervalued stocks.
Does Amgen Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach here projects the cash Amgen could return to shareholders and then compares that stream with today’s $414.87 share price. On this model, the business generated about $10.8b of free cash flow over the last twelve months, and the forecast points to growing annual cash flows that reach the mid teens of billions of dollars by the early 2030s rather than a sharp ramp up or drop off.
Those projections are based on analyst estimates for the next few years, followed by more moderate growth assumptions for the later period. This fits a mature pharmaceutical group with a broad portfolio rather than a single product bet. The KRAS inhibitor push around LUMAKRAS, and Amgen’s backing of Arboretum LifeSciences, helps explain why the DCF model sees room for that future cash generation, because both efforts target areas where precision medicine could support durable demand. The Discounted Cash Flow (DCF) projections put Amgen's estimated intrinsic value substantially above the current share price, which frames the $414.87 market level as a reference point rather than a ceiling or a floor for those long term cash flows. Find out what Amgen could be worth using our Discounted Cash Flow (DCF) estimate.
The Amgen Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Amgen's DCF puzzle leaves off by spelling out the future path for growth, margins and earnings that would need to play out for the stock to be worth materially more or less than today’s price on the Community page. Instead of a single valuation output, these frameworks show the business conditions that figure relies on so you can watch over time whether Amgen's actual progress is tracking that script.
Community views on Amgen are split between a broad platform-led upside story and concern that the stock already prices in near perfect execution.
Bull case: 17% undervalued
"The direct to consumer AmgenNow platform that began with Repatha and now spans multiple medicines has already handled 20,000 patients…"
Discover why this Narrative puts Amgen at 17% undervalued.
Bear case: 15% overvalued
"MariTide's commercial ramp-up will take years post-launch, while Amgen’s high-margin legacy moats (Prolia and Enbrel) are already eroding at a brutal -30%+ YoY clip right now…"
Explore why this Narrative puts Amgen at 15% overvalued.
For Amgen, the people steering the ship matter as much as the sticker price
Valuation models only tell part of the Amgen story, because the track record and incentives of the leaders setting capital priorities can tilt long term outcomes in powerful ways. See who runs Amgen and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com